Tenaya Therapeutics (TNYA) Operating Leases (2021 - 2026)

Tenaya Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 30.79% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 30.79% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 27.89% from the prior year.
• Operating Leases slipped to $7.0 million in Q1 2026 per TNYA's latest filing, from $7.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $13.1 million in Q2 2022 and bottomed at $7.0 million in Q1 2026.
• The 5-year median for Operating Leases is $10.1 million (2025), against an average of $10.1 million.
• Across the five-year window, Operating Leases soared 38.55% in 2025 and tumbled 30.79% in 2026, its largest moves.
• Year by year, Operating Leases stood at $11.1 million in 2022, then retreated by 26.94% to $8.1 million in 2023, then soared by 33.62% to $10.8 million in 2024, then slipped by 27.89% to $7.8 million in 2025, then retreated by 10.35% to $7.0 million in 2026.
• Per Business Quant, the three latest TNYA Operating Leases figures stand at $7.0 million (Q1 2026), $7.8 million (Q4 2025), and $8.6 million (Q3 2025).